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Abstract
Pancreatic beta cells synthesize and secrete the neurotransmitter γ-aminobutyric acid (GABA) as a 
paracrine and autocrine signal to help regulate hormone secretion and islet homeostasis. Islet 
GABA release has classically been described as a secretory vesicle-mediated event. Yet, a 
limitation of the hypothesized vesicular GABA release from islets is the lack of expression of a 
vesicular GABA transporter in beta cells. Consequentially, GABA accumulates in the cytosol. 
Here we provide evidence that the human beta cell effluxes GABA from a cytosolic pool in a 
pulsatile manner, imposing a synchronizing rhythm on pulsatile insulin secretion. The volume 
regulatory anion channel (VRAC), functionally encoded by LRRC8A or Swell1, is critical for 
pulsatile GABA secretion. GABA content in beta cells is depleted and secretion is disrupted in 
islets from type 1 and type 2 diabetic patients, suggesting that loss of GABA as a synchronizing 
signal for hormone output may correlate with diabetes pathogenesis.
INTRODUCTION
The neurotransmitter γ-aminobutyric acid (GABA) occurs at high concentrations in the 
inhibitory neurons of the central nervous system and the pancreatic islets of Langerhans1. 
The physiological purpose of GABA in islets was initially proposed to be a paracrine signal 
released from islet beta cells to inhibit alpha cells2–4. Recent evidence suggests that GABA 
also has strong protective and regenerative effects on the beta cells themselves5. GABA 
increases beta cell mass in rodent and grafted human islets6–11 and ameliorates diabetes in 
non-obese diabetic (NOD) mice12. Additionally, long-term GABA treatment in diabetic 
mice prevents alpha-cell hyperplasia13 and promotes alpha cell trans-differentiation into beta 
cells14,15, although this latter effect is now disputed16,17. Immune cells possess receptors for 
GABA18,19 which suppresses cytokine secretion, inhibits proliferation, and tempers 
migration10,18,20. GABA inhibits autoreactive T cell proliferation at the interstitial 
concentrations found in islets (0.1–10 μM)21–23. Together, this evidence implicates GABA 
as a potent trophic factor and suppressive immunomodulator in islets. It is conceivable that 
the loss of GABA may leave islet regions vulnerable to inflammation20.
GABA is synthesized by the enzyme glutamic acid decarboxylase (GAD), which is 
expressed as two isoforms, GAD65 and GAD67. Human beta cells only express the GAD65 
isoform24, which is detected in the cytosol and anchored to the cytosolic face of Golgi and 
peripheral vesicle membranes by hydrophobic modifications including palmitoylations1,25. 
Earlier low resolution imaging studies localized GAD and GABA to synaptic-like 
microvesicles in beta cells26–28. More recently, GABA has been detected in insulin granules 
from which it is released upon stimulation with glucose to activate GABAA receptors in beta 
cells29–32. However, a substantial fraction of the GABA pool is independent of extracellular 
glucose concentration and yet contributes significantly to GABA signaling in the 
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islet31,33,34. The source of this pool of GABA secretion appears to be the cytosol35, but a 
mechanism linking cytosolic GABA to extracellular release has remained unidentified. In 
analogy to the role ambient GABA plays in the central nervous system36, such release of 
GABA may be crucial for regulating islet cell excitability, coordinating cell activity 
throughout the islet, and producing the beneficial effects mentioned above.
Here, we have assessed how GABA is released from human beta cells. We compared GABA 
release from a predominantly cytosolic pool of intracellular GABA in beta cells with that of 
GABA contained in vesicular membrane compartments including synaptic-like 
microvesicles and the larger insulin secretory vesicles. We provide evidence that cytosolic 
GABA is released from human beta cells via volume regulatory anion channels (VRAC) in a 
pulsatile pattern that is independent of glucose concentration. Furthermore, the GABA-
permissive taurine transporter (TauT) mediates uptake of interstitial GABA. Finally, we 
studied the impact of this non-vesicular GABA release on insulin secretion in human islets 
from non-diabetic and diabetic donors.
RESULTS
Cytosolic pools of GABA are depleted in type 1 and type 2 diabetic islets
Earlier studies have shown that GABA is present at high levels in pancreatic islets35,37, but 
due to the use of glutaraldehyde fixation, the resolution and the ability to use multiple 
antibody labeling of these early images was limited. Using an antibody that does not require 
glutaraldehyde fixation, we studied the GABA content in human islets from non-diabetic 
and diabetic donors. Human pancreas sections from non-diabetic donors immunostained for 
GABA, insulin, and glucagon showed that GABA is highly concentrated in islets compared 
to the surrounding exocrine tissue (Figure 1a). GABA staining was strongest in beta and 
delta cells, while alpha cells contained little or no GABA (Figure 1a,b, Extended Data 1).
Comparing the GABA content in human pancreas sections from non-diabetic (Figure 1c), 
type 2 diabetic (Figure 1d), and type 1 diabetic (Figure 1e,f) donors, we observed that type 1 
and type 2 diabetic islets were depleted of GABA (Figure 1g), a result, which has not been 
previously described. In type 1 diabetic islets, the loss of GABA was not only observed in 
islets devoid of beta cells. Rather, even islets with residual beta cells were depleted of 
GABA (Figure 1f). Taurine, a small molecule compound with molecular characteristics 
similar to GABA, was not depleted in diabetes, indicating that the loss of GABA is unlikely 
caused by varying sample quality or fixation (Extended Data 1). The loss of GABA in type 1 
and type 2 diabetic islets observed by histology was confirmed by high-performance liquid 
chromatography (HPLC) measurements of the GABA content of isolated whole human 
islets from non-diabetic, type 1 diabetic, and type 2 diabetic donors (Figure 1h).
We next addressed whether the lack of GABA in beta cells from type 2 and/or type 1 
diabetic patients was the consequence of a loss of expression of the GABA synthesizing 
enzyme GAD65 (Figure 1i,j). GAD65 immunoreactivity in beta cells of type 2 diabetic 
patients and in remaining beta cells in type 1 diabetes was similar to non-diabetic controls 
(Figure 1k–n). Thus, the lack of GABA in diabetic islets is not due to lack of GAD65 
expression in beta cells.
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In human beta cells, GAD65 was highly expressed in Golgi membranes, peripheral vesicle 
membranes, and the cytosol, while human alpha cells expressed GAD65 at low levels and 
the localization was restricted to ER/Golgi membranes while lacking in vesicle membranes 
and the cytosol (Extended Data 1). Remarkably, alpha cells contained little or no GABA 
(Figure 1a,b) despite expressing GAD65. Expression of GAD65 in alpha cells of diabetic 
pancreases was indistinguishable from non-diabetic pancreases.
Subcellular localization suggests a non-vesicular GABA release mechanism in beta cells
Despites its well-established importance to islet physiology, the dominant mechanism of 
GABA release from islets remains unclear. We searched for immunohistochemical evidence 
of the canonical synaptic-like microvesicle mechanism of GABA-release27,28. In GABA-
ergic neurons, hydrophobic post-translational modifications of the synthesizing enzyme 
GAD65 anchor this protein to the cytosolic face of synaptic vesicle membranes where it 
colocalizes with the vesicular GABA transporter (VGAT)38,39. By association with GAD65, 
VGAT mediates transport of the product GABA into the synaptic vesicle lumen, where it 
accumulates in preparation for regulated secretion40. The existence of an analogous GABA-
secreting system in islet cells would require co-expression of GAD65 and VGAT41 or 
another as-yet unidentified vesicular GABA transporter in synaptic-like microvesicles. We 
found that almost all (> 99%) human beta cells lacked expression of VGAT. VGAT 
expression was, however, detected in a small subset of human beta cells as well as in the 
somatostatin producing delta cells, coinciding with the presence of GABA in vesicular 
compartments. (Figure 2a,b, Extended Data 2)
Human alpha cells were devoid of VGAT. In contrast, in rat islets, VGAT expression was 
mainly detected in alpha cells (Figure 2b, Extended Data 2) while predominantly absent in 
beta and delta cells (Supplementary Table 1). VGAT, also known as the vesicular inhibitory 
amino acid transporter (VIAAT), is a transporter for glycine in addition to GABA in 
neurons40 and in rat alpha cells, where it localizes with glycine in secretory vesicles42. The 
absence of GABA in rat alpha cells in our analyses is consistent with VGAT transporting 
glycine but not GABA in those cells and is in contrast with the results in human delta cells, 
which express VGAT and also contain GABA. A table summarizing the cell type-specific 
expression of GABA, GAD65 and VGAT in human and rat islets is included as 
supplementary information (Supplementary Table 1).
To assess whether VGAT is required for accumulation of GABA in peripheral vesicles, we 
compared the subcellular localization of GABA and GAD65 with synaptic vesicle markers 
synaptophysin, SV2C, and VGAT in monolayers of human islet cells (Figure 2c–i) and in 
hippocampal neurons (Figure 2h,i, Extended Data 2). Almost all human beta cells (~99%) 
exhibited a uniform cytosolic staining pattern for GABA (Figure 2c). However, in the rare 
VGAT+ human beta cells (< 1%; Figure 2d) or in human delta cells (Figure 2e), GABA 
exhibited a well-defined vesicular staining pattern that colocalized with VGAT. The VGAT+/
GABA+ vesicular structures in beta cells colocalized with insulin, but not GAD65, 
identifying them as insulin secretory granules. The existence of a small population of VGAT
+
 beta cells containing GABA in insulin granules reconciles our observations with previous 
reports of quantal exocytotic GABA release events that coincide with insulin release31. 
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These data notwithstanding, the majority of beta cells did not express VGAT and had 
cytosolic rather than vesicular GABA content.
While GABA itself is mainly cytosolic, the GABA-synthesizing enzyme GAD65 exhibits a 
strongly punctate staining pattern in beta cells (Figure 2f)1. These GAD65 puncta in beta 
cells have been previously described as synaptic-like microvesicles27,28. In human or rat 
beta cells containing predominantly cytosolic GABA, there was no concentration of GABA 
in GAD65-positive puncta or in insulin granules (Figure 2f–h). Furthermore, we could not 
identify any marker for synaptic vesicles or endosomes that strongly colocalized with 
GAD65 vesicles or GABA in human or rat beta cells (SV2C, synapsin 6, synaptophysin, 
syntaxin, VAMP2, VGAT, WIPI2, APPL1, caveolin, clathrin, EEA1, GOPC, LAMP1, LC3, 
Rab3c, Rab5, Rab6, Rab7, Rab8, Rab9, Rab10 and Rab11 were tested). Yet, synaptic vesicle 
markers show strong colocalization with both GAD65 and GABA in neurons (Figure 2h,i, 
Extended Data 2). Together, these results indicate that the magnitude of GABA release from 
beta cells does not involve synaptic-like microvesicles.
Islet GABA secretion is pulsatile, and depends on GABA content
To investigate GABA secretion from islets we used cellular biosensors43–45 (Figure 3 and 
Extended Data 3). GABA secretion in real time was monitored by recording intracellular 
Ca2+ mobilization (Δ[Ca2+]i) in biosensor cells stably expressing heteromeric GABAB 
receptors (GABAB R1b and GABAB R2) and the G-protein α subunit, Gαqo546,47 
(Extended Data 3). We found that GABA is secreted from human islets in rhythmic bursts 
(Figure 3a) independent of glucose concentration. Biosensor responses could be blocked by 
the selective GABAB receptor antagonist CGP55845 (10 μM) (Figure 3b) and did not occur 
in the absence of islets (Figure 3a), confirming that the [Ca2+]i responses were elicited by 
GABA released from islet cells. Pulsatile GABA secretion had distinct periods that in most 
islet preparations ranged from 4 to 10 minutes (Figure 3c), similar to pulsatile insulin 
secretion in humans48. The periodicity of GABA secretion varied little between islets from 
the same human islet preparation. Calibrating biosensor responses from islets by comparing 
them to responses evoked by direct application of GABA in the same experiment, GABA 
release from a single islet was estimated to reach local concentrations above 10 μM. In 
conclusion, GABA secretion from islets is robust and pulsatile.
We performed experiments addressing the possibility of conventional Ca2+ dependent 
exocytosis by granules or vesicles31. Stimulating islets with glucose had no effect on 
pulsatile GABA secretion measured by biosensor cells (Figure 3d,e) or on total GABA 
secretion measured by HPLC (Figure 3f, Extended Data 4) (see also33,34). Depolarizing 
islets with KCl (30 mM) or removing extracellular Ca2+ did not affect pulsatile GABA 
secretion (Figure 3g–i). Likewise, depleting extracellular calcium or simultaneously 
depleting intracellular Ca2+ sources with thapsigargin (Figure 3j), stimulating with KCl 
(Extended Data 4), or opening ATP-gated potassium channels with diazoxide (Extended 
Data 4) did not significantly affect GABA secretion from human islets as measured by 
HPLC. Together, these results strongly suggest that Ca2+ (either influx or intracellular 
release) is not a primary trigger for gating of GABA release from the human islet.
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A non-vesicular mode of GABA efflux likely depends on the cytosolic, metabolic pool of 
GABA49,50. Inhibiting GABA biosynthesis with allylglycine (10 mM) acutely diminished 
beta cell GABA content and secretion (Figure 3k,m and Extended Data 5). Increasing the 
intracellular GABA concentration by inhibiting GABA catabolism with γ-vinyl GABA (10 
μM) increased the amount of released GABA per pulse (Figure 3l,m). Thus, the effects of 
manipulating GABA metabolism are surprisingly acute and suggest a high rate of GABA 
biosynthesis that couples GABA efflux to the cytosolic GABA pool34,51–53.
VRAC and TauT transport cytosolic GABA across the plasma membrane in islet cells
In view of the high levels of non-vesicular GABA release from beta cells, we sought to 
determine if membrane transporters contribute to GABA efflux. We analyzed three distinct 
human islet single-cell RNA-seq datasets54–56 for expression of GABA-transporting 
proteins. A phylogenic tree of the neurotransmitter transporter family shows the relationship 
between the membrane GABA transporters (GAT1–3), the betaine-GABA transporter 
(BGT1), and the taurine transporter (TauT) (Figure 4a). GAT1–3 and BGT1 were not 
detected in beta cells (Figure 4b, Extended Data 6). However, TauT, which is also a GABA 
transporter57,58, is highly expressed in beta cells (Figure 4b, Extended Data 6). 
Immunostaining confirmed expression and localization of TauT in the plasma membrane of 
human beta cells (Figure 4c).
We further searched for other putative GABA-transporters across the entire solute channel 
(SLC) gene group (395 members). Relative mRNA expression of all SLC genes in beta cells 
(Supplementary Table 2) revealed that the 4F2 cell-surface antigen heavy chain (4F2HC) 
and its heterodimer partners, LAT1 and LAT2, are highly expressed in beta cells (Figure 4b, 
Supplementary Table 2). We considered LAT2 as a possible GABA transporter due to its 
specificity for the GABA-mimetic drug gabapentin59. Immunostaining confirmed islet-
specific expression and localization of both 4F2HC and LAT2 in the plasma membrane of 
human islet cells (Figure 4d).
Uptake of 3H-radiolabeled GABA (3H-GABA) was measured to assess if either TauT or 
LAT2 mediate inward transport of GABA in human islets (Figure 4e). Competing substrates 
for TauT (10 mM taurine, beta-alanine) or LAT2 (10 mM leucine) were tested for inhibition 
of 3H-GABA uptake. Unlabeled GABA served as a positive control and glycine served as an 
additional control for possible GABA transport by monoamine transporters. Taurine and 
beta-alanine strongly inhibited uptake of 3H-GABA similarly to unlabeled GABA, while 
leucine and glycine were less effective (Figure 4e). Pharmacological inhibition of the 
membrane GABA transport family with a mixture of SNAP5114 (50 μM), NNC05–2090 (50 
μM), and NNC711 (10 μM) also inhibited 3H-GABA uptake. These GAT inhibitors also 
perturbed pulsatile GABA release measured by biosensor cells (Extended Data 4), producing 
an initial transient increase in extracellular GABA levels, indicating that GABA uptake is 
important for maintaining low interstitial levels in the islet. As we were unable to detect 
expression of GAT1–3 in islet cells, we propose that the GAT-blocking drugs acted on 
closely related TauT. Together, the data support the conclusion that TauT is the dominant 
mediator of GABA uptake in islets.
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For GABA release, we looked for expression of known non-canonical GABA transporters, 
including bestrophin chloride channels (BEST1–4)60 and VRAC61. VRAC conveys osmo-
sensitive chloride (Cl−) currents and conducts efflux of GABA, taurine, and other small 
organic osmolytes to regulate cell volume61–64. VRAC complexes are heterohexamers 
composed of multiple LRRC8 family subunits, LRRC8A, B, C, D or E. LRRC8A (also 
known as Swell1) is critical for formation of functional VRAC channels while its heteromer 
partners LRRC8B-E confer substrate specificity61,65. VRAC subunit LRRC8D confers 
permeability to GABA and taurine62. Beta cells express VRAC66–68, with channel subunits 
LRRC8A, LRRC8B, and LRRC8D detected by single-cell RNA-seq (Figure 4b).
To assess whether VRAC channels mediate GABA efflux, human islets were exposed to 
hypo-osmotic buffer and release of endogenous GABA was measured by HPLC (Figure 4f). 
GABA release increased by 3x or 40x upon exposure to increasingly hypotonic buffer 
(Figure 4f). Hypotonic induction of GABA efflux was eliminated from LRRC8A-knockout 
MIN6 beta cells67 and isotonic GABA efflux was reduced by ~50% (Figure 4g–h). These 
results support a mechanism of cytosolic GABA release from islets via VRAC.
To assess whether VRAC in beta cells is responsible for generation of GABA release pulses 
we generated beta-cell specific LRRC8A knockout mice (βc-LRRC8A−/−) by crossing 
LRRC8A floxed mice (LRRC8Afl/fl)67,69 with mice expressing Cre recombinase in insulin-
producing beta cells (Ins1cre)70. Loss of LRRC8A in islets isolated from βc-LRRC8A−/− 
mice was confirmed by Western blot (Figure 4i). βc-LRRC8A−/− islets do not release GABA 
in response to hypotonic stimulus (Figure 4j) consistent with beta cells being the dominant 
GABA-synthesizing cell type in the islet. In wild-type LRRC8A+/− littermates GABA 
release was pulsatile in isotonic conditions and responded to continuous hypotonic 
stimulation with kinetics consistent with VRAC gating62: delayed activation of GABA 
release of 2–3 minutes that builds to a maximum rate of release after ~8 minutes and 
remains active throughout the hypotonic stimulation. Biosensor cell recording of GABA 
release from βc-LRRC8A−/− islets demonstrated both a loss of GABA pulses and loss of 
GABA release under hypotonic stimulus (Figure 4k–l and Extended Data 7). We next 
studied the effect of knocking down LRRC8A in human islets transduced with adenovirus 
encoding LRRC8A shRNA (Ad-mCherry-hLRRC8A-shRNA) or scrambled shRNA (Ad-
mCherry-Scramble-shRNA) (Figure 4l–n). Expression of adenovirus LRRC8A shRNA 
resulted in ~40% decrease in expression of LRRC8A and loss of GABA pulses (Figure 4m–
o). Finally, we used HPLC, a direct detection method, to validate that the kinetics of GABA 
released from human islets under hypotonic stimulation are consistent with previous reports 
of VRAC-mediated organic osmolyte release (Figure 4p)62. Together, these data are 
consistent with a critical role of the LRRC8A component of VRAC in release of GABA 
from the cytosol of beta cells.
Cytosolic GABA secretion synchronizes insulin secretion
GABA has been assigned many functional and regulatory roles in the islet. However, its 
effects on hormone secretion in human beta cells has been a matter of ongoing 
investigation71. We examined the autocrine effects of pulsatile GABA release on insulin 
secretion from human islets. Exposure of human islets at 5 mM glucose to exogenous 
Menegaz et al. Page 7
Nat Metab. Author manuscript; available in PMC 2020 May 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
GABA (10 μM) reduced insulin release by ~40%, suggesting that GABA has an inhibitory 
effect on insulin release under normoglycemic conditions (Figure 5a). We next measured the 
effect of decreasing endogenous GABA release by inhibiting GABA biosynthesis with 
allylglycine (10 mM) (Figure 5b). Inhibition of endogenous islet GABA production 
increased insulin secretion during glucose stimulation (11 mM) (Figure 5b,c), consistent 
with an inhibitory effect of GABA on insulin secretion. Inhibition of endogenous islet 
GABA production did not, however, affect insulin release stimulated by depolarization with 
KCl (Figure 5b), indicating that allylglycine treatment did not disrupt the available pool of 
releasable insulin.
We next measured the effect of GABA on cytosolic Ca2+ responses in human islets. Human 
islets were loaded with Ca2+ indicator dye (Fluo4) and imaged by confocal microscopy 
during glucose stimulation (Figure 5d,e). When GABA was applied during the first phase of 
glucose-induced Ca2+ influx, cytosolic Ca2+ levels were quickly and dramatically reduced to 
near pre-stimulation levels. Islets quickly desensitized within 1–2 minutes to the inhibitory 
effect of applied GABA. These effects are consistent with GABA acting through GABAA 
ionotropic receptors (rather than GABAB metabotropic receptors)72. GABA applied to islets 
in resting glucose conditions (3 mM) had no effect on beta cell Ca2+ calcium responses.
To test the effects of GABA on coordinated pulsatile insulin secretion, we measured 
serotonin release as a surrogate for insulin secretion73–77 using CHO cells expressing the 
serotonin receptor 5-HT2C78,79. As we and others have reported77,79–81, serotonin/insulin 
secretion from human islets was pulsatile with regular periods ranging from 4 to 10 minutes 
(Figure 5f). When we decreased endogenous GABA levels and release from cells by 
inhibiting GABA biosynthesis with allylglycine (10 mM), basal serotonin/insulin secretion 
increased and failed to display regular secretory pulses (Figure 5f,h). Decreasing catabolism 
of GABA and increasing endogenous GABA levels by adding γ-vinyl-GABA (10 μM), 
inhibited pulsatile serotonin/insulin secretion (Figures 5g,h). Similarly, blocking GABAA 
receptor signaling with the inhibitor SR 95531 (10 μM) disrupted the periodicity of 
serotonin pulses (Figure 5i). These results indicate that GABA production and paracrine 
GABAergic signaling within the islet impacts periodic insulin secretion.
By expressing the lumenal protein of large dense core vesicles neuropeptide Y (NPY) fused 
to the pH-dependent green fluorescent protein pHluorin in beta cells, we visualized 
exocytotic events in real time82,83 and observed periodic exocytotic bursts occurring 
simultaneously throughout the islet with periods of ~ 5 minutes. In the presence of the 
GABAA receptor agonist muscimol (100 μM) these exocytotic events became smaller and 
lost synchronicity (Figures 5j,k).
Thus, using four different methods, we provide evidence that endogenously produced GABA 
released from a cytosolic beta cell pool decreases insulin release while stabilizing the 
periodicity and glucose responsiveness of insulin secretion.
Cytosolic GABA secretion is interrupted in human islets from type 2 diabetic donors
As shown in Figure 1, immunostaining of human islets from type 2 diabetic donors revealed 
depletion of GABA pools in beta cells in spite of robust expression of the biosynthesizing 
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enzyme GAD65. We examined multiple preparations from human type 2 diabetic donors for 
GABA release with biosensor cells (n ≥ 3 islets from each of the 5 donors). Consistent with 
the immunostaining results, we could not detect pulsatile GABA secretion from human islets 
from type 2 diabetic donors (Figure 6a,b). Type 2 diabetic islets did respond to KCl 
depolarization as evidenced by strong increase in cytosolic Ca2+, indicating they were alive 
and retained membrane potentials (Figure 6c). By contrast, pulsatile GABA secretion was 
robust in islets from non-diabetic donors (Figure 6a, see also Figure 3). Pulsatile GABA 
secretion from islets of type 2 diabetic patients could be rescued by inhibiting GABA 
catabolism with γ-vinyl GABA (10 μM) (Figure 6d–e). The periodicity of insulin release, 
measured by serotonin co-release detected via biosensor cells, was deranged in type 2 
diabetic islets (Figure 6f,g). This effect was similar to that elicited by blocking GABA 
signaling in non-diabetic islets by inhibiting GABAA receptors with SR 95531 (Figure 5i). 
Insulin secretion periodicity in type 2 diabetic islets became more regular upon treatment 
with γ-vinyl GABA (Figure 6g).
We previously reported the accumulation of GAD65 in Golgi membranes of beta cells 
undergoing ER stress through perturbations of the palmitoylation cycle that controls 
targeting of the enzyme to peripheral vesicles84. Similar accumulation and defect in 
membrane compartment distribution was detected in individuals experiencing early as well 
as late phases of GAD65 autoimmunity and development of type 1 diabetes84. We examined 
the intracellular distribution of GAD65 by confocal microscopy of immunostained sections 
of human pancreas. GAD65 was detected in both the cytoplasm and Golgi compartment in 
beta cells in sections from non-diabetic donors (Figure 6h), but showed increased 
localization to the Golgi compartment in beta cells of type 2 diabetic patients (Figure 6i,j).
DISCUSSION
Our study provides evidence for a novel mechanism of GABA release in human beta cells. 
As a result of enzymatic synthesis of GABA from glutamic acid by GAD65, GABA is 
present at high levels in the cytoplasm of beta cells. It is from this cytosolic pool that GABA 
is released, because only ~1% of the beta cells show evidence of VGAT expression and the 
consequent accumulation of GABA in secretory vesicles. Our study shows that GABA in the 
islet behaves as an organic osmolyte. Indeed, in the islet, GABA shares transport properties 
with the canonical organic osmolyte taurine, namely efflux via VRAC and uptake via the 
taurine transporter. We further found that islet GABA levels are greatly reduced under 
diabetic conditions. Given the paracrine, islet-trophic, and immunosuppressive roles of 
GABA, the loss of islet GABA content in both type 1 and type 2 diabetes may contribute to 
beta cell loss and dysfunction.
Several mechanisms can be suggested to cause the low levels of islet GABA in human 
diabetes. First, while the GAD67 isoform binds the co-enzyme 5’pyridoxal phosphate (PLP) 
firmly and is a constitutively active holoenzyme, GAD65 oscillates between an active 
holoenzyme and an inactive apo-enzyme85,86. Thus, it is possible that GAD65 is mainly 
present as an inactive apo-enzyme in beta cells under diabetic conditions. Second, GAD65 
may be rendered inactive in beta cells by expression or formation of an inhibitor. Third, 
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GABA metabolism, rather than GAD65 expression, may be a dominant factor controlling 
islet GABA content in beta cells in diabetic conditions.
GAD65 anchors to the cytosolic face of intracellular membranes25. The shift in localization 
of the enzyme to perinuclear ER/Golgi membranes observed in beta cells in human diabetes 
would not be expected to prevent release of the product GABA into the cytosol unless the 
enzyme in Golgi membranes represents the inactive GAD65 apoenzyme or is associated 
with an inhibitor. The consequent decrease in synthesis of cytosolic GABA would interrupt 
GABA transport and prevent pulsatile GABA secretion. This possibility would be consistent 
with our observations in human alpha cells, which are devoid of GABA, yet express GAD65 
that appears to localize exclusively to ER/Golgi membranes.
Expression of the synaptic vesicle markers VGAT and synaptophysin in islets87,88 has 
contributed to the concept that GABA is secreted from beta cells via synaptic-like 
microvesicles28. Here, using an approach that allows for high resolution subcellular 
localization studies, we show that almost all beta cells (> 99%) lack synaptic-like vesicles or 
granules containing VGAT together with GAD65 and/or GABA. A small subset of beta cells 
(< 1%) exhibit all features of vesicular GABA. The nature of the small subpopulation of 
VGAT-positive beta cells is currently unknown but may intersect with markers of beta cell 
subtype and/or maturation state. It is possible that its size is variable and subject to presently 
unknown factors which could affect its contribution to the vesicular release of GABA 
described earlier26,31,89. However, it appears that in the vast majority of beta cells, GABA is 
released from the cytosolic pool via plasma membrane channels.
Pertinent to our findings, Rorsman and Pipeleers have previously reported a high rate of 
basal (non-quantal) GABA release that was unregulated by glucose or pharmacological 
regulators of insulin secretion31,34,90. Due to this unregulated GABA release, it was 
concluded that the beta cell must be equipped with a second pathway for release of GABA 
that is non-vesicular, the details of which remained to be elucidated31,90. Here, we have 
identified VRAC to be a pathway for GABA release that is consistent with the findings by 
Rorsman and Pipeleers.
While glucose-inducible VRAC Cl− currents have been observed in beta cells67,68, no effect 
of glucose has been reported for LRRC8A-dependent organic osmolyte efflux. This may be 
because LRRC8A-dependent Cl− and organic osmolyte efflux are not required to follow the 
same behavior. For example, organic osmolyte and Cl− currents can occur through different 
isoforms of the VRAC channel. LRRC8A/D is the dominant channel for GABA release and 
LRRC8A/B/C/E channels exhibit low GABA conductance but high Cl− conductance62,65. It 
remains to be determined if multiple isoforms of VRAC exist simultaneously in beta cells or 
if the same VRAC channel can differentially gate Cl− and organic osmolytes depending on 
the activating conditions. Another explanation for why we do not observe glucose-mediated 
effects on GABA release may be that the degree of swelling required to activate the GABA 
VRAC channel is greater than obtained by glucose-stimulation. The Jentsch group reported 
that a very high, non-physiological glucose stimulation (25 mM = 450 mg/dl) induced 
comparatively moderate beta cell swelling (only 1/4 of the volume differential of hypotonic 
stimulation) and no clear subsequent regulatory volume decrease68. The Sah group obtained 
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similar results, where they showed that 16.7 mM glucose induces only a minor beta cell 
swelling of 6.8% in murine beta cells with a sluggish associated volume response, and no 
clear trend of glucose on human beta cell swelling67. If regulatory volume decrease is 
required for organic osmolyte efflux via VRAC, then this lack of a regulatory volume 
decrease upon glucose stimulation is consistent with our observation that glucose does not 
induce GABA release.
Our findings indicate that endogenously released GABA has two major effects on beta cells: 
(A) it reduces insulin secretion and (B) it helps stabilize the periodicity of insulin pulses. 
That GABA has inhibitory effects on beta cells was further supported by experiments in 
which GABA and the GABAA receptor agonist muscimol were added exogenously and is 
consistent with findings by Birnir and colleagues71. Similar to the role somatostatin is 
proposed to play in the islet91,92, GABA may serve to change the gain of insulin secretion 
and thus prevent its wasteful release. The pulsatile pattern of GABA efflux and its impact on 
the periodicity of insulin secretion suggest an additional role for GABA in timing or pacing 
of oscillatory islet activities. As shown by our results, restoring GABA signaling in type 2 
diabetic islets improves the synchronicity of insulin secretory pulses but diminishes their 
magnitude. Conversely, the loss of GABA in diabetic states is likely to produce increases in 
the excitability of beta cells that will help increase insulin secretion, but at the price of losing 
periodicity. While continuous pulsatile GABA release may contribute to the economy and 
periodicity of insulin secretion under normal conditions, it remains to be determined if the 
dramatic reduction in GABA levels is a mechanism that helps the beta cell increase insulin 
secretion and hence cope with the increased demand in diabetic states.
Our findings that GABA inhibits insulin secretion and beta cell Ca2+ responses differ from 
those showing that GABA depolarizes beta cells and increases insulin secretion31. The 
discrepancy can be explained by different experimental conditions (e.g. dynamic hormone 
secretion measurements versus static incubation, different basal glucose concentrations). 
That GABA has been reported to depolarize beta cells to ~ −50 mV31, however, indicates 
that GABA will clamp the membrane potential below the threshold for the opening of P/Q 
type Ca2+ channels (above −20 mV), the channels that are responsible for insulin granule 
exocytosis93. Our findings are further in line with results showing that GABA stimulates 
delta cells31, which leads to secretion of the potent inhibitory hormone somatostatin. 
Importantly, beta cells also express inhibitory metabotropic GABAB receptors whose 
activation opens hyperpolarizating K+ channels or inhibit adenylyl cyclases94. Therefore, 
there is substantial evidence supporting an inhibitory role for GABA in human beta cells.
It is likely that many physiological processes within the islet, including local actions of 
secreted GABA and of other paracrine signals31,43,44, shapes islet cell excitability, as 
described for neurons in the central nervous system36,95. In addition to the effects on insulin 
secretion reported here, non-vesicular GABA secretion also affects the activities of the 
glucagon-secreting alpha cell and the somatostatin-secreting delta cell27,96. Because GABA 
stimulates delta cells to secrete somatostatin and because somatostatin strongly inhibits 
insulin secretion, a pulse of GABA may both inhibit beta cells directly and indirectly via 
delta cells. Recent findings by the Sah and Jentsch groups demonstrate that knockout of 
LRRC8A, the GABA releasing pathway we report here, impairs glucose-responsive insulin 
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secretion in contrast to our finding that GABA is inhibitory to beta cells67,68. A possible 
explanation for this discrepancy is that insulin secretion is an event requiring integration of 
multiple signals. Sah and Jentsch both showed that loss of LRRC8A also affects beta cell 
membrane potential and delays or impairs beta cell Ca2+ responses. As GABA appears to 
only be inhibitory to beta cells during glucose-responsive Ca2+ fluxes, any loss of inhibition 
from impaired GABA release may be overwhelmed by the stronger inhibition imposed by 
LRRC8A knockout. Thus, the functional effect of a loss of GABA is observable by blocking 
GABA biosynthesis, as we have shown, but not by preventing GABA release through VRAC 
knockout.
Intracellular GABA levels and cytosolic GABA release are dramatically decreased in type 1 
(Figure 1) and type 2 diabetes (Figures 1, 6), indicating that islets lose the paracrine, trophic, 
and immunomodulatory influence of GABA in the diabetic state. It is conceivable that this 
loss of GABA leaves islets vulnerable to destructive inflammation. We propose that a 
periodic pattern of cytosolic GABA release independent of glucose concentration impacts 
the magnitude and periodicity of insulin secretion. Interrupting GABA secretion impairs 
coordination of hormone secretion. Irregular insulin secretion from the islet may exacerbate 
insulin resistance48. Given its inhibitory effect on alpha cells, defective GABA signaling97 
and decreased GABA secretion could also explain why glucagon secretion is increased in 
type 2 diabetes, causing further elevation of hyperglycemia. Thus, loss of GABA signaling 
in the islet may contribute to the pathogenesis of type 1 and 2 diabetes. Because restoring 
GABA signaling can be proposed as an intervention point to promote islet function, our 
study has implications for a novel pharmaceutical strategy for the treatment of diabetes. In 
rodent islets electrical coupling via gap junctions and purinergic paracrine signaling have 
been suggested to coordinate rhythmic insulin secretion48. Here we show, however, that in 
the human islet GABA is a potential pacemaker candidate because (1) it is released 
independently of glucose concentration in pulses with a frequency in the range of those of 
pulsatile in vivo insulin secretion; (2) it is a diffusible factor acting on GABAA receptors 
whose activation inhibits beta cell activity; and (3) its production and release can regulate 
the periodicity of insulin secretion.
METHODS
Human pancreas tissues
Human pancreatic sections from tissue donors of both genders were obtained via the 
Network for Pancreatic Organ Donors with Diabetes (nPOD) tissue bank, University of 
Florida, Gainesville, FL, USA. Human pancreata were harvested from cadaveric organ 
donors by certified organ procurement organizations partnering with nPOD in accordance 
with organ donation laws and regulations and classified as “Non-Human Subjects” by the 
University of Florida Institutional Review Board (IRB No. 392–2008) waiving the need for 
consent98,99. nPOD tissues specifically utilized for this project were approved as non-human 
by the University of Florida Institutional Review Board (IRB No. 201701113).
Human pancreatic islets were obtained from deceased non diabetic donors and from donors 
with type 2 diabetes from the Human Islet Cell Processing Facility at the Diabetes Research 
Institute at the University of Miami Miller School of Medicine, from the NIDDK-funded 
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Integrated Islet Distribution Program (IIDP) at City of Hope, from the European Consortium 
on Islet Transplantation (ECIT) Islets for Basic Research Program, and from Prodo 
Laboratories, Inc. Human pancreatic islets from deceased donors with type 1 diabetes were 
isolated by the nPOD Islet Isolation Program (IIP). Human islets received from the 
University Hospital of Geneva and San Raffaele Scientific Institute, Milan through the ECIT 
islets for basic research program were approved by the Institutional Review Board of the 
University Hospital of Geneva (CER No. 05–028) and by the Ethics Committee of the San 
Raffaele Scientific Institute of Milan (IPF002–2014). The University of Geneva and the San 
Raffaele Institute Ethics Committees waived the need for consent from the donors because 
islets were used for experimental research only when not suitable for clinical purposes and 
would otherwise have been destined for destruction. In such cases obtaining informed 
consent is not mandatory in Switzerland and Italy. Cadaveric human islets for research were 
approved as non-human by the University of Florida Institutional Review Board (IRB No. 
201702860).
Human islets were cultured at 24°C in 10 cm non-adherent cell culture dishes (500 islets/
dish) in CMRL medium with 2% glutamine, 10% FBS, 10 mM HEPES and 1% Penicillin/
Streptomycin.
Rat pancreatic islets
All experimental protocols using rat islets were approved by the University of Florida and 
EPFL Animal Care and Use Committees. Rat islets were isolated from pancreases of male 
and female P5 Sprague Dawley rats (Charles River) in accordance with published methods1. 
Rat pups were sacrificed by decapitation and the whole pancreas was removed and digested 
in 0.15 mg/ml Liberase TL (Roche #05401020001) in HBSS (Hank’s buffered salt solution, 
Gibco #24020091) + 20 mM HEPES for 7 minutes with strong manual agitation. The 
Liberase enzyme was stopped with addition of HBSS + 20 mM HEPES + 0.5% fetal bovine 
serum (FBS). Digested pancreas tissue was washed four times with HBSS + 20 mM HEPES 
+ 0.5% FBS at 4°C, resuspended in Histopaque-1119 (Sigma #11191), overlain with HBSS 
+ 20 mM HEPES + 0.5% FBS (room temperature), and centrifuged for 20 min at 300 x g at 
20°C. Islets were collected from the interface between Histopaque and HBSS phases and 
washed 3x with HBSS + 20 mM HEPES + 0.5% NBCS. Islets were then hand-cleaned with 
a 200 μl pipette and cultured in 10 cm non-adherence petri dishes at 37°C 5% CO2, 500 
islets per dish, 9 ml RPMI 1640 medium with GlutaMAX (Gibco #61870010), 10% FBS, 
1% Penicillin/Streptomycin.
LRRC8A knockout mouse islets
All experimental protocols using transgenic mice were approved by the University of Florida 
Animal Care and Use Committee. Experimental protocols using transgenic mouse islets 
were approved by the University of Florida Animal Care and Use Committee. LRRC8A-
floxed (LRRC8Afl/fl) mice on the C57BL/6NCrl background were generated in and provided 
by Rajan Sah’s labs at the University of Iowa and Washington University in St. Louis67,69. 
LRRC8Afl/fl mice were crossed with mice expressing Cre recombinase in beta cells 
(Ins1cre)70 purchased from The Jackson Laboratory (B6(Cg)-Ins1tm1.1(cre)Thor/J; Stock 
#026801) to generate beta cell specific LRRC8A-knockout (βc-LRRC8A−/−) mice. Mouse 
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genotypes were confirmed by PCR using published primers67,69,70 and loss of LRRC8A in 
islets was confirmed by Western blot. βc-LRRC8A−/− mice (8–14 weeks old) were 
sacrificed by cervical dislocation under deep isoflurane anesthesia according to the approved 
procedures. Heterozygous LRRC8A+/− Cre-expressing littermates served as wild-type 
controls. Equal numbers of male and female mice were used. The pancreas was perfused via 
the common bile duct with 2–3 ml HBSS containing Liberase TL (0.15 mg/ml), removed, 
and digested at 37 °C for an initial 12 minutes, disrupted by pipetting up and down several 
times with a 10 mL pipette, and digested for a final 4 minutes. The enzyme digestion was 
quenched with HBSS + 10% FBS. Islets were purified from digested tissue and cultured 
using the same methods as described for rat islets.
Islet cell monolayer culture
Within one week of isolation, rat or human islets were hand-picked from suspension 
cultures, collected in a 15 ml tube and washed twice in PBS without Ca2+ and Mg2+. Islets 
were dissociated into a suspension of single islet cells by continuous gentle pipetting in 0.3 
ml 0.05% trypsin-EDTA per 500 islets for 3 minutes at 37 °C. Trypsin digestion was halted 
by addition of islet monolayer medium (Minimum essential medium (MEM) with 
GlutaMAX 11 mM glucose, 5% FBS, 1 mM sodium pyruvate, 10 mM HEPES and 1x B-27 
Supplement) to a total volume of 15 ml, followed by pelleting of islet cells by centrifugation 
for 5 min at 1400 rpm (350 × g) and resuspension islet monolayer medium. Islet cells were 
seeded on round 12 mm diameter and 0.17 mm thickness borosilicate glass coverslips 
(Electron Microscopy Sciences) coated with purified laminin (Gibco) or purified collagen IV 
(Sigma Aldrich) at 50 μg/ml in HBSS with Ca2+/Mg2+ for 1 hour at 37 °C. Cells were 
seeded at approximately 35,000 cells/cm2. Islet cells required 3–4 days of culture to adhere 
and spread on surfaces before further experimentation. A detailed description and validation 
of monolayer cultures of primary human and rat islets cells is available100.
Hippocampal neuron cultures
Primary rat hippocampal neurons were prepared from P2-P3 Sprague Dawley rats of both 
sexes, as described by Codazzi, et al101. Neurons were seeded on round poly-L-ornithine-
coated glass or Thermanox coverslips (Nunc), at 100,000 cells per coverslip in a 24-well 
plate and in 1 ml of neuronal medium: Minimum essential medium (MEM) with GlutaMAX 
(Gibco), 11 mM glucose, 5% FBS, 1 mM sodium pyruvate, 10 mM HEPES and 1x B-27 
Supplement53 (Gibco). One day after isolation, 3 μM of the chemotherapeutic agent ARA-C 
(Sigma-Aldrich) was added to the culture medium to eliminate astrocytes and obtain a 
neuronal culture of high purity (>90% neurons).
Immunofluorescence staining
Human pancreas sections obtained from nPOD were deparaffinized followed by acidic-pH 
heat-mediated antigen retrieval according to the nPOD standard operating procedure for 
immunopathology. Monolayers of pancreatic islet cells were fixed with 4% EM-grade PFA 
(Electron Microscopy Sciences) at room temperature for 20 minute. Samples were blocked 
and permeabilized in PBS + 0.3% Triton X-100 with 10% goat or donkey serum. Primary 
antibodies were incubated overnight in PBS + 0.3% Triton X-100 with 1% goat or donkey 
serum at 4°C. Alexa Fluor 405, 488, 568, and 647 conjugated secondary antibodies (Thermo 
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Fisher) were incubated at 1:200 dilution in PBS + 0.3% Triton X-100 for 30 minutes at room 
temperature. Coverslips were mounted with ProLong Gold Antifade Reagent with or without 
DAPI (Thermo Fisher).
Immunostaining for GABA and taurine was validated by competitive inhibition of primary 
antibody binding by addition of soluble GABA or taurine to the antibody incubation buffer 
(Extended Data 6). The anti-GABA and anti-taurine antibodies showed minimal non-
specific binding towards non-GABA or non-taurine amino acids. Furthermore, GABA 
immunostaining was eliminated by inhibition of the GABA-synthesizing enzyme, GAD65, 
with allylglycine (Extended Data 5).
Microscopy
Confocal images (pinhole = airy 1) of randomly selected islets (2–3 islets per section) were 
acquired on a confocal laser-scanning microscope (Zeiss LSM700, Zeiss LSM710, Leica 
SP5, and Leica SP8) with 20x/0.8 NA Plan-Apochromat air, 40x/1.30 and 63x/1.40 NA 
Plan-Apochromat oil-immersion objectives at 1024 × 1024 pixel resolution. Images were 
processed and quantified in ImageJ. Manders’ coefficient colocalization analyses were 
performed using the JACoP (Just Another Colocalization Plugin) plugin for ImageJ102. To 
determine the subcellular localization of GAD65, the intensity of GAD65 immunostaining 
in the Golgi compartment of beta cells in pancreata from healthy donors was compared to 
that of pancreata from T2D donors. Using ImageJ software, we measured GAD65 staining 
intensity in the whole cells as well as in the Golgi apparatus by selecting a region of interest 
based on the Golgi staining signal. GAD65 immunostaining was always more intense in the 
Golgi apparatus than in the cytosol. To allow comparisons between tissue sections and 
specimens, we expressed the mean GAD65 staining intensity in the Golgi compartment 
relative to the intensity of GAD65 staining in the whole beta cell [ΔGAD65 = (mean 
GAD65 intensity in Golgi – mean GAD65 intensity in whole cell) / mean GAD65 intensity 
in whole cell].
Gene expression analysis
Raw molecular counts per gene and cell were directly obtained from GEO (accession 
numbers GSE84133, GSE81076, and GSE83139), and further normalized using the R 
package scran103. Results were qualitatively similar across the three datasets. 
Log(norm_values+1) corresponding to GSE81076 are displayed in Figure 4 and GSE84133 
and GSE83139 in Extended Data 6.
Detection of GABA via biosensor cells
We adapted real time measurements of GABA secretion from Dvoryanchikov et al104. 
GABA biosensor cells were obtained from Novartis Institutes for BioMedical Research in 
Switzerland. GABA biosensor cells consisted of Chinese hamster ovary (CHO) cells stably 
expressing heteromeric GABAB (GABAB R1b and GABAB R2) receptors and the G-protein 
α subunit, Gαqo5 modified to couple to increases in [Ca2+]i via the InsP3 signaling cascade 
(Extended Datas 3,7). GABA biosensor cells reliably responded to low concentrations of 
GABA (threshold ≈ 100 nM), making them highly sensitive GABA detectors. GABA 
biosensor cell responses were measured using [Ca2+]i imaging. We loaded GABA 
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biosensors with the [Ca2+]i indicator Fura-2 and plated them on poly-d-lysine coated cover 
slips in a perfusion chamber. Individual human islets were placed on top of this layer of 
biosensor cells. Fluid perfusion was performed with a gravity-driven Warner Instruments 
VC-8 8-channel perfusion system set to 0.5–1 ml/min and connected to a Warner 
Instruments RC-20 closed bath small volume imaging chamber to ensure linear solution 
flow and fast exchange. GABA secretion was examined in biosensors cells located 
immediately downstream of the islet in recordings lasting at least 20 minutes to be able to 
detect rhythmic behavior. GABA secretion was examined for pulses simply by inspecting 
recordings for robust increases in [Ca2+]i in biosensor cells. Because the pulse amplitudes 
were large, no deconvolution or other processing of the raw [Ca2+]i traces was necessary. We 
calculated the periods between pulses by measuring the time between the initial rises in 
[Ca2+]i in at least three sequential pulses per biosensor cell. The regularity of the pulses was 
quantified by using the deviation of this interpulse interval. Changes in the amount of 
secreted GABA were quantified by measuring the area under the curve of the [Ca2+]i 
responses in the biosensor cells during defined time intervals. These analyses were only 
performed within the same experiment because quantitative comparisons between 
experiments would have required calibration with known concentrations of GABA. Only 
recordings with at least three responsive biosensor cells were included in the analyses. 
Secretion was considered coordinated and pulsatile if the responses in the biosensor cells 
were synchronized and showed regular periods. We expressed these data as average traces of 
the [Ca2+]i responses of the biosensor cells.
We established that biosensor cells responded only to GABA and not to other substances 
including taurine. Of all the tested substances, only GABA activated the biosensor. 
Crucially, the antagonist CGP (10 μM) completely blocked GABAB receptors on the GABA 
biosensors and eliminated responses generated from islets. Stimuli or pharmacological 
agents (e.g. antagonists, transporter blockers) used in this study did not themselves either 
elicit biosensor responses or alter the ability of biosensors to respond to GABA. We 
conducted these controls by [Ca2+]i imaging of biosensor cells plated at low density and in 
the absence of islets. When examining pulsatile secretion it was important to establish that 
biosensor cells themselves did not display periodic behavior in the absence of islets or in the 
continuous presence of GABA. Biosensor cells for acetylcholine, which are also CHO cells, 
did not show oscillatory responses in the presence of islets44, indicating that oscillatory 
signals are not an intrinsic property of these cells but stem from the islet’s secretory 
behavior. The effects of manipulation were compared to controls recorded in the same 
experimental session or using islets from the same human islet preparation to compensate 
for the variability in the quality of islets. To ensure that islets were healthy, we 
simultaneously monitored [Ca2+]i responses in islets and biosensor cells. KCl depolarization 
induced responses in islets but not in biosensor cells, indicating that islet cells were viable. 
False negative results were ruled out by confirming that biosensor cells remained fully 
responsive to GABA at the end of the recording session.
Detection of insulin via biosensor cells
To detect insulin release we used an approach in which serotonin is used as a surrogate for 
insulin. Serotonin is present in insulin granules and is released with insulin73–77,81. 
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Biosensor cells for serotonin were CHO cells expressing the serotonin receptor 5-HT2C and 
are further described and characterized in previous publications78,79.
Determination of cytosolic Ca2+ concentration
Imaging of cytoplasmic [Ca2+] ([Ca2+]i) was performed in accordance with published 
descriptions105. Islets, dispersed islet cells, or biosensor cells were incubated in Fura-2 AM 
(2 μM; 1 hour) and placed in a closed small-volume imaging chamber (Warner Instruments, 
Hamden, CT). Stimuli were applied with the bathing solution. Cells loaded with Fura-2 were 
alternatively excited at 340 and 380 nm light and fluorescence was recorded on two different 
microscope setups. At the University of Miami, we used a monochromator light source 
(Cairn Reseach Optoscan Monochromator, Cairn Research Ltd, Faversham, UK). Images 
were acquired with a Hamamatsu camera (Hamamatsu Corp, Japan) attached to a Zeiss 
Axiovert 200 microscope (Carl Zeiss, Jena, Germany). Changes in the 340/380 fluorescence 
emission ratio were analyzed over time in individual cells using MetaFluor imaging 
software. At the University of Florida, we used a pE-340fura LED illumination system 
(CoolLED Ltd., Andover, UK) and a Hamamatsu ORCA-Flash 4.0 LT+ camera attached to a 
Zeiss Axio Observer Z1 microscope. Change in the 340/380 fluorescence emission ratio 
were analyzed over time in individual cells using Zeiss Zen 2.3 blue edition software.
Insulin secretion during perifusion
A high-capacity, automated perifusion system was used to dynamically measure insulin 
secretion from pancreatic islets (Biorep Perifusion V2.0.0, Miami, FL). A low pulsatility 
peristaltic pump pushed KRBH solution at a perifusion rate of 100 μL/min through a column 
containing 100 pancreatic islets immobilized in Bio-Gel P-4 Gel (BioRad, Hercules, CA). 
Except otherwise stated, glucose concentration was adjusted to 3 mM for all experiments. 
Stimuli were applied with the perifusion buffer. The perifusate was collected in an automatic 
fraction collector designed for a 96 well plate format. The columns containing the islets and 
the perifusion solutions were kept at 37°C, and the perifusate in the collecting plate was kept 
at < 4°C. Perifusates were collected every minute. Insulin release in the perifusate was 
determined with the human or mouse Mercodia Insulin ELISA kit following manufacturer’s 
instructions.
KRBH Buffer preparation
Kreb’s ringer bicarbonate HEPES (KRBH) buffer (115 mM NaCl, 4.7 mM KCl, 2.5 mM 
CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, 25 mM HEPES, 0.2% BSA, 3 
mM glucose) was prepared containing final concentrations of solutes according to 
Supplementary Table 3. Theoretical osmolarity was calculated according to the following 
expression106:
osmolarity =∑
i
φi ni Ci Equation 1.
Where: φ is the osmotic coefficient, n is the number of particles (e.g. ions) into which a 
molecule dissociates, C is the molar concentration of the solute, and i is the identity of a 
particular solute. Osmolarities of solutions were verified using an osmometer and found to 
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be in good agreement with theoretical calculations. Isotonic KRBH had an osmolarity of 294 
mOsmol/L.
Detection of GABA by HPLC with electrochemical detector
Fractions collected from islet perifusion in the BioRep islet perifusion device or supernatants 
from static incubations in KRBH buffer were analyzed for GABA content using an EICOM 
HTEC-500 HPLC-ECD with autosampler, online automated OPA-derivatization, and 
Eicompak FA-3ODS separation column. This automated detection technique is linearly 
sensitive for GABA from the nano-molar to milli-molar range107. Insulin content in the 
same sample fraction was determined by ELISA kit (Mercodia). Data shown in Figure 3f 
analyzed GABA content from perifusion fractions while data shown in Figures 3j, 4f,h,j, and 
Extended Data 4a,b,c are from static incubations. Each sample (for all cases) contained 
approximately 100 IEQ. Perifusion flow rate was 100 μL/min. Static incubations were 
performed in 100 μL KRBH 3 mM glucose for 30 minutes.
LRRC8A knockout MIN6 cells
Wild-type and LRRC8A (also known as Swell1) knockout MIN6 beta cells generated by 
CRISPR/Cas9 technology67 were provided by Rajan Sah’s lab at the University of Iowa and 
Washington University in St. Louis. Confirmation of LRRC8A gene disruption by PCR, 
LRRC8A protein deletion, and ablation of LRRC8A-mediated current in these cells was 
published by the Sah group67. MIN6 cells cultured in DMEM with 15% FBS and 1% 
penicillin streptomycin were transfected with human GAD65-GFP plasmid39 using 
Lipofectamine 2000.
Adenovirus
Human adenoviruses type 5 with hLRRC8A-shRNA (Ad5-mCherry-U6-hLRRC8A-shRNA) 
and a scrambled non-targeting control (Ad5-U6-scramble-mCherry) were obtained from 
Vector Biolabs. Adenovirus was added to human islets in culture (final concentration of 5 × 
107 PFU/ml) and incubated for 24 h. The islets were then washed with PBS three times and 
cultured for 1–2 days before performing further experiments. Transduction efficiency was 
assessed by fluorescence microscopy.
Western blotting
Cell lysates were prepared by extraction of whole islets or MIN6 cells in RIPA buffer 
(Sigma). The BCA protein assay kit (Thermo Fisher Scientific) was used to measure the 
protein concentration of cell extracts. Gel electrophoresis was performed with the NuPAGE 
system (Life Technologies) with transfer onto polyvinylidene fluoride membranes with the 
iBlot 2.0 (Life Technologies) device. Membranes were blocked with 5% nonfat milk in tris 
buffered saline, incubated in primary antibody overnight at 4°C, and detected with 
secondary antibody (LI-COR Biosciences). Blots were imaged on the LI-COR Odyssey CLx 
scanner.
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Real-time recording of exocytosis
To image exocytosis, an adenovirus was engineered, encoding for an endogenous protein of 
large dense core vesicles neuropeptide Y (NPY) fused to pHluorin, a pH-dependent green 
fluorescent protein108. Human islets infected with this virus were cultured short term (1 
week) to permit exogenous adenoviral protein expression while retaining islet cell function. 
The NPY-pHluorin fusion protein was correctly localized to granules, and the pH-dependent 
fluorescence of pHluorin was retained. The NPY-pHluorin fusion protein exploits the 
granule luminal pH changes that occur during exocytosis to visualize exocytotic events of 
live islet cells in real time with high spatial resolution in three dimensions82.
Statistical Analysis
All measurements were taken from distinct samples. Means among three or more groups 
were compared by analysis of variance (ANOVA) in GraphPad Prism 8 software. If deemed 
significant, Tukey’s post-hoc pairwise comparisons were performed. Means between two 
groups were compared by two-tailed Student’s t-test. Variances between two groups were 
compared by F test. A confidence level of 95% was considered significant. The statistical 
test used, exact P-values, and definition of n, are all indicated in the individual figure 
legends. All error bars in the figures display the mean ± s.e.m.
Reagents
The following antibodies were utilized for immunofluorescence staining:
gp-α-insulin (Linco #4011–01), gp-α-insulin (Dako #A0564), ck-α-insulin (Abcam 
#ab14042), sh-α-glucagon (Abcam#ab36232), sh-α-somatostatin (Abcam #ab35425), rb-α-
pancreatic polypeptide (Abcam #ab113694), rb-α-GABA (Sigma-Aldrich #A2052), ms-α-
GAD65 C-term109 (in-house RRID:AB_528264), ms-α-GAD65 N-term110 (Christiane 
Hampe Lab), rb-α-GAD65 (Synapic Systems #198102), gp-α-GAD65 (Synaptic Systems 
#198104), rb-α-TauT (Sigma-Aldrich #HPA015028), rb-α-VGAT Oyster 650-labeled 
(Synaptic Systems #131103C5), rb-α-synaptophysin (Abcam #ab14692), rb-α-SV2C 
(Synaptic Systems #119202), rb-α−4F2HC (Santa Cruz Biotech. #sc9160), ms-α-LAT2 
(OriGene #UM500058), rb-α-Bestrophin 1 (Abcam #ab14928), rb-α-GAT1 (Synaptic 
Systems #274102), rb-α-GAT2 (Abcam #ab2896), rb-α-GAT3 (Synaptic Systems #274303), 
rb-α-GCP60 (Novus Biologicals # NBP1–83379), rb-α-taurine (Sigma-Aldrich #AB5022), 
Alexa Fluor conjugated secondary antibodies (Thermo Fisher).
The following antibodies were utilized for Western blotting:
rb-α-LRRC8A (Cell Signaling #24979), ms-α-beta actin (Sigma-Aldrich #A1978), IRDye 
conjugated secondary antibodies (LI-COR, Inc).
gp = guinea pig, ck = chicken, ms = mouse, rb = rabbit, sh = sheep
The following chemicals were utilized:
CGP 55845 hydrochloride (Tocris Bioscience #1248/10), γ-vinyl GABA (Tocris #0808), L-
allylglycine (Sigma-Aldrich #A7762), SR 95531 hydrobromide (Tocris #1262), Niflumic 
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acid (Tocris #4112/50), CFTRinh 172 (Tocris #3430/10), NNC711 (Tocris #1779/10), SNAP 
5114 (Tocris #1561/10), NNC05–2090 hydrochloride (Tocris #2747/10), Tetrabenazine 
(Tocris #2175), Diazoxide (Tocris # 0964), GABA (Sigma-Aldrich #A5835), Serotonin 
(Sigma-Aldrich #14927), DIDS (Sigma-Aldrich #D3514), 3H-GABA (Perkin-Elmer 
#NET191250UC), Muscimol (Tocris #0289), Liberase TL (Roche #05401020001), 
Histopaque-1119 (Sigma-Aldrich #11191)
Reporting Summary
Further information on research design is available in the Nature Research Reporting 
Summary linked to this article.
Data availability
The unique biological materials used in the manuscript are available from the corresponding 
authors upon reasonable request with the exception of those materials that the authors 
obtained via a materials transfer agreement (MTA) that prohibits transfer to third parties; 
these include the GABA biosensor cells (obtainable from Dr. Klemens Kaupmann, Novartis 
Institute for BioMedical Research, Basal, Switzerland), LRRC8A−/− MIN6 cells and 
LRRC8Afl/fl mice (obtainable from Dr. Rajan Sah, Washington University in St. Louis, 
U.S.A.), and NPY- pHluorin (obtainable from Dr. Herb Gaisano, University of Toronto, 
Canada). Other requests for materials should be addressed to corresponding authors Drs. 
Steinunn Baekkeskov, Alejandro Caicedo or Edward Phelps.
The data that support the findings of this study are available from the corresponding authors 
upon reasonable request.
Extended Data
Menegaz et al. Page 20
Nat Metab. Author manuscript; available in PMC 2020 May 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Extended Data Fig. 1. Delta cells in human islets contain GABA and express GAD65; taurine 
content is preserved in diabetic islets
a-b. Islets in a non-diabetic human pancreas immunostained for GABA and somatostatin (a); 
or GAD65 and somatostatin (b). GABA and GAD65 are present in somatostatin producing 
human delta cells. Scale bar 50 μm. Right panels show higher magnification views of the 
boxed region showing channels for: (a) (1) GABA only, (2) somatostatin only, and (3) 
GABA and somatostatin; (b) (1) GAD65 only, (2) somatostatin only, and (3) GAD65 and 
somatostatin. Images are representative of data plotted in Figures 1b and 1j. Scale bar 20 
μm.
c. Quantification of taurine mean fluorescence intensity (MFI) per islet in confocal images 
of human pancreas sections from non-diabetic (n = 21 islets, 6 donors), type 2 diabetic (n = 
24 islets, 8 donors), and type 1 diabetic donors (n = 24 islets, 8 donors). Background 
(BKGD) indicates average taurine MFI in acinar tissue outside of the islet. One-way 
ANOVA: ND vs. T2D (*P = 0.0430), ND vs. T1D (ns, P = 0.6667). Center line indicates the 
mean.
d. Human pancreas sections immunostained for taurine, insulin, and glucagon from a non-
diabetic, type 2 diabetic and, type 1 diabetic donor. Left panels show insulin and glucagon 
channels, while right panels show taurine channel from the same image. Images are 
representative of the dataset plotted in panel c. Scale bars 50 μm.
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e. Representative confocal image of a monolayer of human islet endocrine cells showing 
immunostaining for GAD65, insulin, and glucagon (left panel) and GAD65 alone (right 
panel). Images are representative of 3 human islet preparations. Scale bar 20 μm.
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Extended Data Fig. 2. VGAT expression is concentrated in delta cells of human islets and alpha 
cells of rat islets; GABA colocalizes with GAD65 and VGAT in synaptic vesicles in neurons.
a-b. Islets in a non-diabetic human pancreas (a) and rat pancreas (b) immunostained for 
VGAT, insulin, glucagon, somatostatin, and pancreatic polypeptide. VGAT is absent in most 
beta cells but present in somatostatin producing human delta cells and glucagon producing 
rat alpha cells. Results are representative of the dataset plotted in Figure 1b. Scale bar 50 
μm.
c. Rat hippocampal neuron immunostained for GABA and the GABA biosynthesizing 
enzyme GAD65. Scale bar 10 μm. Right panels show higher magnification views of the 
boxed region showing channels for: (1) GABA only; (2) GAD65 only; (3) GABA and 
GAD65. GAD65 and GABA colocalize in vesicles. Results are representative of n = 3 rat 
neuron preparations. Scale bar 5 μm.
d. Rat hippocampal neuron immunostained for GAD65 and the vesicular GABA transporter 
VGAT, which is present in synaptic vesicle membranes. Scale bar 10 μm. Right panels show 
higher magnification views of the boxed region showing channels for: (1) GAD65 only; (2) 
VGAT only; (3) GAD65 and VGAT. GAD65 and VGAT colocalize in synaptic vesicles. 
Results are representative of n = 3 rat neuron preparations. Scale bar 5 μm.
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Extended Data Fig. 3. Characterization of GABA biosensor cells for detecting GABA released 
from human islets.
a. Schematic and image of the GABA biosensor cell assay setup (left panel). Biosensor cells 
consist of CHO cells stably expressing the heteromeric GABAB receptor (GABAB R1b and 
GABAB R2) and the G-protein α subunit, Gαqo5 to allow for GABA detection by 
intracellular Ca2+ mobilization (Δ[Ca2+]i) (right panel). GABA biosensor cells are pre-
loaded with the [Ca2+]i indicator Fura-2 and plated on poly-d-lysine coated cover slips in a 
perfusion chamber. Individual islets are placed on top of this layer of biosensor cells and 
connected to a closed bath small volume imaging chamber to ensure linear solution flow and 
fast exchange.
b. Titration of exogenous GABA showing concentration-dependence of Ca2+ flux in GABA 
biosensor cells. The plot shows the average 340/380 Fura-2 ratio of n = 5 GABA biosensor 
cells in the same field of view. Mean ± SEM.
c. Effect of the selective GABAB receptor antagonist CGP5584 on biosensor cell responses 
to exogenously applied GABA. n = 5 biosensor cells in the field of view. Mean ± SEM.
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d. Biosensor cell intracellular Ca2+ responses remain elevated during sustained (30 min) 
exposure to GABA (100 μM shown). n = 5 GABA biosensor cells in the field of view. Mean 
± SEM.
e. GABA release from a human islet maintained in 3 mM glucose. n = 5 GABA biosensor 
cells located under or immediately downstream of the islet. This is a representative trace of 
experiments performed on 40 human islet preparations. Mean ± SEM.
f. Biosensor cells have tonic responses to continuously applied GABA and phasic responses 
to GABA pulses released from islets. Periods of pulsatile GABA release measured from n = 
22 human islet preparations, ≥ 3 islets per preparation (black circles) as shown in panel e. 
Calculated periods for biosensor cell responses to continuously applied GABA (gray circles) 
at 0.1, 1, 10, and 100 μM GABA as shown in panel d. Center line indicates the mean.
g. GABA release from a human islet maintained in 3 mM glucose without addition of 
inhibitors. n = 5 GABA biosensor cells located under or immediately downstream of the 
islet. This is a representative trace of experiments performed on 40 human islet preparations. 
Mean ± SEM.
h. Effect of the selective GABAB receptor antagonist CGP5584 on biosensor cell detection 
of GABA released from a single human islet. n = 5 GABA biosensor cells located under or 
immediately downstream of the islet. Trace is representative of 3 independent experiments 
with different human islet preparations. Mean ± SEM.
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Extended Data Fig. 4. GABA release does not depend on glucose but is activated by VRAC 
opening.
a-b. Titration of glucose concentrations from 0–25 mM has no effect on islet GABA release. 
HPLC quantification of GABA released from rat (a) and human (b) islets during 30 mins 
static incubation in KRBH of the indicated glucose concentrations. n = 4 samples of 100 
islets. One-way ANOVA, P = 0.5563 rat (a), P = 0.2053 human (b), ns = not significant. 
Mean ± SEM.
c. HPLC quantification of GABA released from human islets in 5.5 mM glucose (n = 4 
samples of 100 human islets), 30 mM KCl (n = 3 samples of 100 human islets), or diazoxide 
(100 μM) (n = 4 samples of 100 human islets). One-way ANOVA, P = 0.1511, ns = not 
significant. Mean ± SEM.
d. Effect of the GAT inhibitors SNAP5114 (50 μM), NNC05–2090 (50 μM), and NNC711 
(10 μM) on biosensor detection of GABA secretion from a human islet. GAT inhibitors were 
present throughout the shaded portion of trace. Results are representative of the data plotted 
in panel e.
e. Quantification of GABA release following treatment with GAT inhibitors. Box extends 
from 25th to 75th percentiles, center line represents the median, whiskers represent smallest 
to largest values. n = 3 islets, One-way ANOVA, 0–20 min vs. 20–40 min (*P = 0.002), 0–20 
min vs. 40–60 min (*P = 0.9194), 0–20 min vs. 60–80 min (*P = 0.0058).
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Extended Data Fig. 5. Allylglycine inhibition of beta cell GABA content and secretion.
a-b. Validation of GABA antibody via immunostaining of paraformaldehyde-fixed rat 
hippocampal neurons (a) or rat islet cell monolayers (b) for GAD65, GABA, and insulin (not 
shown) without or with addition of soluble GABA to the primary antibody incubation buffer; 
or without or with preincubation of cells with allylglycine (10 mM) to inhibit GABA 
biosynthesis. Images are representative of 3 experimental replicates. Scale bars 20 μm.
c. Immunostaining of paraformaldehyde-fixed rat islets cell monolayers for GABA, insulin, 
and GAD65, following allylglycine (10 mM) addition and removal. Images are 
representative of the dataset plotted in panel d.
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d. Quantification of GABA mean fluorescence intensity (MFI) in rat islet cell monolayers in 
allylglycine timecourse experiments shown in panel c. n = 4 coverslips. Mean ± SEM.
e. HPLC analysis of GABA release from human islets during a 30 min addition of 
allylglycine (no pre-incubation). n = 3 samples of ~100 islets each. Statistical analysis by 
two-tailed t-test, *P = 0.0104. Mean ± SEM.
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Extended Data Fig. 6. Human islet single-cell RNA-seq for expression of genes of interest.
a. Expression of neurotransmitter transporter family genes (SLC6A). Mean ± SEM.
b. Expression of genes of interest reported in the literature as related to GABA or putative 
GABA membrane transporters. Mean ± SEM. Data shown are from two datasets54,55, but 
results agree with and are representative of three different curated human single-cell RNA-
seq datasets analyzed54–56 (see also Figure 4).
Menegaz et al. Page 29
Nat Metab. Author manuscript; available in PMC 2020 May 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Extended Data Fig. 7. Kymographs of individual GABA biosensor cells.
a-b. Still image, kymographs, and average trace from timelapse videos of Fura-2 [Ca2+]i 
signals in GABA biosensor cells in a perfusion flow field in 3 mM glucose isotonic KRBH 
exposed to (a) 0.1, 1, and 10 μM GABA, (b) downstream from a wild type mouse islet, and 
(c) downstream from a βc-LRRC8A−/− mouse islet. GABA (1 μM) is added to (c) at 23 min. 
GABA-responsive cells were selected for analysis, while unresponsive cells were not 
analyzed. Data are representative of three independent experiments. See also Supplementary 
Videos 1–3.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Cytosolic pools of GABA are depleted in type 1 and type 2 diabetic islets
a. A human pancreatic islet from a non-diabetic donor immunostained for GABA, insulin, 
and glucagon. Image is representative of the dataset plotted in panel b. Scale bar 50 μm. 
Right panels show higher magnification. Scale bar 10 μm.
b. Quantification of GABA colocalization with insulin (n = 15 islets, 9 donors), glucagon (n 
= 15 islets, 8 donors), and somatostatin (n = 15 islets, 3 donors) in human islets. One-way 
ANOVA: insulin vs. glucagon (*P < 0.0001), insulin vs. somatostatin (*P = 0.0182). Center 
line indicates the mean.
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c-f. Human islets immunostained for GABA, insulin, and glucagon from a non-diabetic (c), 
type 2 diabetic (d), type 1 diabetic (e), and a type 1 diabetic donor with residual beta cell 
mass (f). Images are representative of the dataset plotted in panel g. Scale bars 50 μm.
g. Quantification of GABA mean fluorescence intensity (MFI) per human islet from non-
diabetic (n = 15 islets, 9 donors), type 1 diabetic (n = 15 islets, 8 donors), and type 2 diabetic 
donors (n = 12 islets, 8 donors). Background (BKGD) indicates average GABA MFI in 
acinar tissue outside of the islet. One-way ANOVA: ND vs. T2D (*P < 0.0001), ND vs. T1D 
(*P < 0.0001). Center line indicates the mean.
h. High performance liquid chromatography (HPLC) quantification of GABA content for 
human islet preparations from non-diabetic (n = 8 donors), type 2 diabetic (n = 3 donors), 
and type 1 diabetic donors (n = 2 donors). One-way ANOVA: ND vs. T2D (*P = 0.0196), 
ND vs. T1D (*P = 0.0106). Center line indicates the mean.
i. Human islet from a non-diabetic donor immunostained for GAD65, insulin, and glucagon. 
Image is representative of the dataset plotted in 1j. Scale bar 50 μm.
j. Quantification of GAD65 colocalization with insulin (n = 24 islets, 9 donors), glucagon (n 
= 24 islets, 9 donors), and somatostatin (n = 11 islets, 3 donors) in human islets. One-way 
ANOVA: insulin vs. glucagon (*P < 0.0001), insulin vs. somatostatin (*P = 0.0257). Center 
line indicates the mean.
k-m. Human islets immunostained for GAD65 from non-diabetic, type 2 diabetic, and type 
1 diabetic donors. Images are representative of the dataset plotted in panel n. Scale bars 50 
μm.
n. Quantification of GAD65 mean fluorescence intensity (MFI) per human islet from non-
diabetic (n = 23 islets, 9 donors), type 1 diabetic (n = 23, 8 donors), and type 2 diabetic 
donors (n = 24 islets, 8 donors). Background (BKGD) indicates average GAD65 MFI in 
acinar tissue outside of the islet. One-way ANOVA: ND vs T2D (*P = 0.0380), ND vs. T1D 
(ns, P = 0.9511), T2D vs. T1D (ns, P = 0.0817). Center line indicates the mean.
Menegaz et al. Page 39
Nat Metab. Author manuscript; available in PMC 2020 May 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. Subcellular localization suggests a non-vesicular GABA release mechanism in beta cells
a. A human islet from a non-diabetic donor immunostained for VGAT, insulin, and 
somatostatin. Image is representative of the dataset plotted in panel b. Scale bar 50 μm. 
Right panels show higher magnification views. Scale bar 10 μm.
b. Expression of VGAT is strongest in human delta cells and rat alpha cells but rare in beta 
cells of either species. Human islets stained for VGAT and insulin (n =8 islets, 3 donors), 
glucagon (n = 7 islets, 3 donors), and somatostatin (n = 5 islets, 3 donors). Rat islets stained 
for VGAT and insulin (n =7 islets, 3 donors), glucagon (n = 6 islets, 3 donors), and 
Menegaz et al. Page 40
Nat Metab. Author manuscript; available in PMC 2020 May 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
somatostatin (n = 6 islets, 3 donors). One-way ANOVA, insulin vs. somatostatin, human (*P 
< 0.0001), insulin vs. glucagon, rat (*P < 0.0001). Center line indicates the mean.
c. GABA is non-vesicular and cytosolic in almost all human beta cells. A VGATNEG 
primary human beta cell immunostained for GABA, VGAT, and insulin (not shown). Image 
is representative of n = 3 human islet preparations, ≥ 3 samples per preparation. Scale bar 50 
μm. Right panels show higher magnification views. Scale bar 2 μm.
d. A rare VGATPOS primary human beta cell showing colocalization of GABA and VGAT in 
vesicular structures. Image is representative of n = 3 human islet preparations, ≥ 3 samples 
per preparation. Scale bar 50 μm. Bottom panels show higher magnification views. Scale bar 
2 μm.
e. A primary human delta cell immunostained for GABA, VGAT, and somatostatin (not 
shown) showing colocalization of GABA and VGAT in vesicular structures. Image is 
representative of n = 3 human islet preparations, ≥ 3 samples per preparation. Scale bar 50 
μm. Bottom panels show higher magnification views. Scale bar 2 μm.
f-g. GABA is present in the cytosol and does not colocalize with insulin or GAD65 in 
vesicular structures in primary human (f) or rat (g) beta cells immunostained for GABA, 
insulin, and GAD65. Images are representative of n = 3 islet preparations, ≥ 3 samples per 
preparation. Scale bar 10 μm. Inset images show single-channel higher magnification views. 
Scale bar 2 μm.
h. Colocalization analyses between GAD65 (green) and the synaptic vesicle markers 
synaptophysin, SV2C, and VGAT (red) or GABA (red) in primary human beta cells, primary 
rat beta cells, and primary rat hippocampal neurons. Images are representative of data 
plotted in 2i. Scale bar 2 μm.
i. Quantification of colocalization in human beta cells for GAD65 with markers of synaptic 
vesicles synaptophysin (n = 14), SV2C (n = 3), and VGAT (n = 10); in primary rat beta cells 
(n = 11, 10, and 10); and primary rat hippocampal neurons (n = 6, 11, and 11). While 
GAD65 positive vesicles in rat neurons colocalize with synaptic vesicle markers, 
colocalization is rare or absent in human and rat beta cells. human beta cells:. Two-way 
ANOVA: human beta cells vs rat neurons for all markers (*P < 0.0001), rat beta cells vs. rat 
neurons for all markers (*P < 0.0001).
Menegaz et al. Page 41
Nat Metab. Author manuscript; available in PMC 2020 May 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. Islet GABA secretion is pulsatile and depends on GABA content
a. GABA release from a human islet maintained in 3 mM glucose, detected by cytosolic 
Ca2+ flux in GABAB receptor-expressing biosensor cells (black trace). Biosensor cell 
responses to no islets or to GABA only are shown for comparison (blue traces). Unless 
otherwise specified, in this and all subsequent Figures, the plot shows the average 340/380 
Fura-2 ratio from ≥ 5 GABA biosensor cells located under the islet, hereafter labeled as 
GABA release. This is a representative trace of experiments performed on n = 40 human 
islet preparations.
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b. The GABAB receptor antagonist CGP55845 (10 μM) blocks biosensor cell detection of 
GABA pulses from a single human islet. Results are representative of n = 3 human islet 
preparations, ≥ 3 islets per preparation.
c. Periods of pulsatile GABA release measured from n = 22 human islet preparations, ≥ 3 
islets per preparation. Mean ± SEM.
d. Representative trace of GABA release pulses from a human islet at different glucose 
concentrations (1G = 1 mM, 3G = 3 mM, 11G = 11 mM). Results are representative of data 
plotted in panel e.
e. Quantification of traces shows no difference in the amount of released GABA per pulse at 
different glucose concentration (n = 3 islet preparations, 18–20 islets per each preparation). 
One-way ANOVA: 1G vs. 3G (ns, P = 0.6181), 1G vs. 11G (ns, P = 0.1684), 3G vs. 11G (ns, 
P = 0.5302). Mean ± SEM.
f. Insulin and GABA released during human islet perifusion. GABA and insulin were 
quantified in the same sample by HPLC and ELISA (n = 3 samples of 100 islets each). One-
way ANOVA: for insulin release, 3G vs. 16.7G (*P = 0.0046), 3G vs. KCl (*P = 0.0007); for 
GABA release, 3G vs. 16.7G (ns, P = 0.5034), 3G vs. KCl (ns, P = 0.2341).
g. Islet GABA secretory pulses before and during (shaded area) KCl depolarization (30 
mM). Trace is representative of n = 3 human islet preparations, ≥ 3 islets per preparation.
h. Islet GABA secretory pulses in the presence and absence (shaded area) of nominal Ca2+. 
Trace is representative of n = 3 human islet preparations, ≥ 3 islets per preparation.
i. Quantification of GABA release during KCl depolarization and absence of nominal Ca2+ 
compared to control (n = 15 islets, 3 donors). Two tailed t-test: KCl vs. hypothetical mean of 
1.0 (*P = 0.0069), 0 Ca2+ vs. hypothetical mean of 1.0 (ns, P = 0.1202). Mean ± SEM.
j. HPLC quantification of GABA release from human islets in the presence and absence of 
nominal Ca2+, with or without thapsigargin (10 μM) inhibition of intracellular Ca2+ (n = 4 
samples of 100 islets each). One-way ANOVA: control vs. 0 Ca2+ (ns, P = 0.5231), control 
vs. 0 Ca2+ + thapsi (ns, P = 0.2946), 0 Ca2+ vs. 0 Ca2+ + thapsi (ns, P = 0.8851). Mean ± 
SEM.
k. Trace of GABA release from a human islet before (black trace) and after (red trace) 
applying the GAD65 inhibitor allylglycine (10 mM). Trace is representative of n = 3 islet 
preparations, ≥ 3 islets per preparation.
l. Trace of GABA release from a human islet before (black trace) and after (green trace) 
applying the GABA transaminase inhibitor γ-vinyl GABA (10 μM). Trace is representative 
of n = 3 islet preparations, ≥ 3 islets per preparation.
m. Quantification of GABA release from human islets treated with allylglycine or γ-vinyl 
GABA. (n = 3 islet preparations, ≥ 4 islets per preparation). Two-tailed student’s t-test: 
control vs. allylglycine (*P = 0.0353), control vs. γ-vinyl GABA (*P = 0.0411). Mean ± 
SEM.
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Figure 4. VRAC and TauT transport cytosolic GABA across the plasma membrane in beta cells
a. Phylogenetic tree diagram of human SLC6A neurotransmitter transporter family 
members.
b. Gene expression for SLC6A and other proteins of interest for GABA transport and 
biosynthesis in human beta cells from an analysis of a curated human islet single-cell RNA-
seq dataset (n = 158 cells)56. Mean ± SEM. Results are representative of three different 
human single-cell RNA-seq datasets analyzed (Extended Data 6 and Supplementary Table 
1).
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c. Representative confocal image of a human pancreas section immunostained for TauT and 
insulin. Scale bar 50 μm. Right panels show higher magnification views of the boxed region 
with individual channels for (1) TauT and (2) insulin. Image is representative of n = 3 
donors, ≥ 3 islets per donor. Scale bar 20 μm.
d. Representative confocal microscopy images of an islet in a human pancreas section 
immunostained for LAT2 (upper panel) and 4F2HC (lower panel). Scale bar 50 μm. Right 
panels show higher magnification views of the boxed region showing individual channels for 
(1) LAT2 and (2) 4F2HC. Image is representative of n = 3 donors, ≥ 3 islets per donor. Scale 
bar 20 μm.
e. Uptake of radiolabeled 3H-GABA by human islets with competitive inhibition from 
unlabeled GABA, taurine, beta-alanine, leucine, or glycine; or blocking the GABA 
transporters with a mixture of SNAP5114 (50 μM), NNC05–2090 (50 μM), and NNC711 
(10 μM) (GAT blockers) (n = 3 samples of 500 islets each). One-way ANOVA: control vs. 
GABA (*P < 0.0001), control vs. taurine (*P < 0.0001), control vs. β-alanine (*P < 0.0001), 
control vs. glycine (*P < 0.0001), control vs. GAT blockers (*P < 0.0001), control vs. 
leucine (#P = 0.0139). Data are representative of 3 islet preparations (2 human, 1 rat). Center 
line indicates the mean.
f. HPLC measurement of cumulative GABA and taurine release from human islets in KRBH 
buffer of varying osmolarity (n = 3 samples, 100 islets each). One-way ANOVA: for GABA, 
300 vs. 160 mOsm/L (*P < 0.0001), 300 vs. 250 mOsm/L (*P = 0.0288). Data are 
representative of 4 human islet preparations. Center line indicates the mean.
g. Western blot for LRRC8A and β-actin in WT and LRRC8A−/− MIN6 insulinoma cells. 
Results are representative of 3 independent immunoblots with similar results.
h. HPLC measurements of rate of GABA release from wild type (WT) or LRRC8A−/− 
MIN6 insulinoma cells during static incubation in 3 mM glucose isotonic (300 mOsm/L) or 
hypotonic (250 mOsm/L) KRBH buffer (n = 3 samples of 40,000 cells each). WT and 
LRRC8A−/− MIN6 cells were transfected with a plasmid encoding human GAD65 24 hours 
prior to the experiment as they do not endogenously express either GAD65 or GAD67. Two-
way ANOVA: WT iso vs. WT hypo (*P < 0.0001), WT iso vs. LRRC8A−/− iso (*P = 
0.0053), LRRC8A−/− iso vs. LRRC8A−/− hypo (ns, P = 0.2974). Center line indicates the 
mean.
i. Western blot for LRRC8A in mouse islets isolated from WT (LRRC8A+/− littermates 
heterozygous for floxed allele) and beta cell-specific knockout (βc-LRRC8A−/−) mice. 
Western blot was performed once using islets pooled from 2 donors of each genotype.
j. HPLC measurements of cumulative GABA release from WT and βc-LRRC8A−/− mouse 
islets in 3 mM glucose isotonic (300 mOsm/L) or hypotonic (250 mOsm/L) KRBH buffer. n 
= 3 samples of 20 islets each. Two-way ANOVA: WT iso vs. WT hypo (*P < 0.0001), βc-
LRRC8A−/− iso vs. βc-LRRC8A−/− hypo (ns, P = 0.8057). Mean ± SEM.
k. Biosensor cell traces of GABA release from WT and βc-LRRC8A−/− mouse islets during 
isotonic and prolonged (10 min+) hypotonic stimulation. Islets used for these experiments 
were confirmed for loss of LRRC8A by Western blot (panel g). Results are representative of 
data plotted in panel l.
l. GABA release detected by biosensor cells from WT (n = 5) and βc-LRRC8A−/− (n = 3) 
mouse islets. Data are representative of two independent islet isolation. Two-way ANOVA of 
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log transformed data: WT iso vs. WT hypo (*P = 0.0003), WT iso vs. βc-LRRC8A−/− iso 
(*P = 0.0003), βc-LRRC8A−/− iso vs. βc-LRRC8A−/− hypo (ns, P = 0.9999). Mean ± SEM.
m. Western blot for LRRC8A in human islets infected with Ad-mCherry-Scramble-shRNA 
or Ad-mCherry-hLRRC8A-shRNA adenovirus. Western blot was performed once.
n. Knockdown of LRRC8A in human islets reduces basal GABA pulses. Results are 
representative of the data plotted in panel o.
o. Quantification of biosensor cell detection of GABA release from human islets infected 
with Ad-mCherry-Scramble-shRNA (n = 3 islets) or Ad-mCherry-hLRRC8A-shRNA (n = 6 
islets). Data are representative of two independent human islet preparations. Two-tailed t-test 
(*P = 0.0065). Mean ± SEM.
p. HPLC measurement of dynamic GABA release from nondiabetic human islets during 
isotonic (300 mOsm/L) and prolonged hypotonic (250 mOsm/L) stimulation. n = 3 samples 
of 100 islets each. Mean ± SEM.
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Figure 5. Cytosolic GABA secretion synchronizes insulin secretion
a. Human islet perifusion in 5 mM glucose showing reversible inhibition of insulin secretion 
in response to exogenous GABA (10 μM). n = 3 islet preparations. Mean ± SEM.
b. Human islet perifusion showing differential glucose-stimulated insulin response in islets 
treated with GAD65 inhibitor allylglycine (10 mM, red trace) vs. control (black trace). n = 3 
islet preparations. Mean ± SEM.
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c. Quantification from islet perifusion during 11 mM glucose stimulation phase, control 
(black trace), with allylglycine (red trace). n = 3 islet preparations (average of > 3 islets per 
preparation), Two-tailed t-test, *P = 0.0175. Mean ± SEM.
d. Four independent traces of cytosolic Ca2+ levels measured by Fluo-4 dye in human islets 
during successive addition of 3 mM glucose, 16.7 mM glucose, and GABA (10 μM). GABA 
induces a rapid drop of cytosolic Ca2+ that desensitizes after ~90s. Data are representative of 
three human islet preparations.
e. Quantification of ΔCa2+ levels in human islets under 16.7 mM glucose stimulation during 
the first 2 minutes after addition of GABA. n = 4 islets. Two-tailed t-test, *P = 0.0132. Mean 
± SEM.
f. Effect of GAD65 inhibitor allylglycine (10 mM) on serotonin/insulin secretion from 
human islets at 3 mM glucose concentration using serotonin biosensor cells. Trace is 
representative of experiments performed in n = 3 human islet preparations, ≥ 3 islets/
preparation.
g. Effect of the GABA transaminase blocker γ-vinyl GABA (10 μM) on serotonin/insulin 
secretion from human islets at 3 mM glucose concentration. Ca2+ trace is representative of 
experiments performed in n = 3 human islet preparations, ≥ 3 islets/preparation.
h. Quantification of serotonin/insulin secretion from human islets treated with allylglycine 
or γ-vinyl GABA from experiments performed. n = 3 human islet preparations, ≥ 3 islets/
preparation. One-way ANOVA, *P < 0.0001. Mean ± SEM.
i. Periodicity of serotonin/insulin secretion from human islets (n = 28 biosensor cells) and 
the increase in periodicity variance in the presence of the GABAA receptor antagonist SR 
95531 (10 μM) (n = 35 biosensor cells). Data are pooled from 3 independent human islet 
preparations, > 3 islets/preparation. Two-sided F test to compare variances, *P = 0.0002. 
Mean ± SEM.
j. Traces of the sum of fluorescent exocytotic signals in three individual beta cells from 
different islet regions showing periodic, synchronous exocytosis at 16 mM glucose (left) and 
asynchronous, diminished exocytosis after adding the GABAA receptor agonist muscimol 
(100 μM, right). Traces are representative of n = 3 islet preparations, ≥ 3 islets per 
preparation.
k. Quantification of the amplitude of beta cell fluorescent exocytotic signals in islets treated 
with muscimol. n = 3 human islet preparations, ≥ 3 islets/preparation, all measurements 
depicted. Two-tailed t-test, *P < 0.0001. Mean ± SEM.
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Figure 6. Cytosolic GABA secretion is interrupted in human islets from type 2 diabetic donors
a. Absence of GABA secretion detected by biosensor cells from an islet taken from a type 2 
diabetic donor (black trace), but distinct GABA secretion is detected from an islet from a 
non-diabetic donor (gray trace). Addition of exogenous GABA to a type 2 diabetic islet 
induces a strong response from biosensor cells. Representative of experiments performed in 
5 islet preparations from type 2 diabetic donors and 40 non-diabetic donor preparations, ≥ 3 
islets/preparation.
b. Quantification of GABA release from non-diabetic (n = 4) and type 2 diabetic (n = 5) 
human islets. Two-tailed t-test, *P = 0.0418. Mean ± SEM.
c. Ca2+ flux in diabetic human islets during stimulation with KCl. Representative of 
experiments performed in 5 islet preparations from diabetic donors.
d. Pulsatile GABA release from an islet from a type 2 diabetic donor before (black trace) 
and after (green trace) exposure to the GABA transaminase inhibitor γ-vinyl GABA (10 μM, 
1 hour). Representative of n = 5 islets.
e. Quantification of GABA release pulse amplitude from type 2 diabetic human islets before 
and after exposure to γ-vinyl GABA. n = 3 human islet preparations (average of ≥ 3 islets/
preparation). Two-tailed t-test, *P = 0.0257. Mean ± SEM.
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f. Insulin/serotonin release detected by serotonin biosensor cells from an islet from a type 2 
diabetic donor before (black trace) and after (green trace) exposure to γ-vinyl GABA (10 
μM, 1 hour). Representative of n = 5 islets.
g. Periods of insulin/serotonin release from islets from a type 2 diabetic donor before (black 
dots) and after (green dots) exposure to γ-vinyl GABA (10 μM, 1 hour) from experiments 
performed as in (f). n = 5 islets. Two-tailed t-test to compare means, *P = 0.01, two-sided F 
test to compare variances, *P = 0.0118. Mean ± SEM.
h-i. Confocal images of islets from non-diabetic (h) and type 2 diabetic donors (i) 
immunostained for GAD65 and Golgi resident protein GCP60. Arrows point at GAD65 
accumulation in Golgi membranes. Images are representative of data plotted in panel j. Scale 
bar 10 μm.
j. Quantification of GAD65 immunostaining intensities in Golgi membranes in beta cells of 
pancreata from non-diabetic and type 2 diabetic donors. GAD65 staining in Golgi 
membranes is expressed relative to the total cellular GAD65 staining (ΔGAD65). n = 18 
islets from 3 donors per group. Two-tailed t-test, *P < 0.0001. Mean ± SEM.
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